Medical cannabis for the treatment of fibromyalgia syndrome: a retrospective, open-label case series

Table 11 Dosage of THC and CBD administered with dominant THC medical cannabis to fibromyalgia patients

Patient	THC-dominant MC (Bedrocan, FM1, Pedanios), N= 18
	Decoction		Oil extract
	THC (mg)	CBD (mg)	THC (mg)	CBD (mg)
Patient #1	22	0
Patient #2	132	0
Patient #3	22	0
Patient #4			9.69	0
Patient #5	66	0
Patient #6	100.8	2.4
Patient #7
Patient #8	53.4	1.2
Patient #9	22	0
Patient #10
Patient #11	99	0	34.2	0
Patient #12	52.8	0.3
Patient #13	46.2	0
Patient #14	44	0	8.55	0
Patient #15	22	0
Patient #16	35.2	0
Patient #17
Patient #18
Median	46.2	0	9.7	0
IQR	60.5	0.15	25.65	0
Mean	55.2	0.3	17.5	2
± SD	35.4	0.7	14.5	1.3

MC medical cannabis, THC Δ-9-tetrahydrocannabinol, CBD cannabidiol, N number of patients, IQR interquartile range, ± plus/minus, SD standard deviation. The table shows the quantity of Δ-9-tetrahydrocannabinol and cannabidiol administered with THC-dominant medical cannabis to 18 patients with fibromyalgia syndrome treated with medical cannabis for at least 3 months at an Italian pain clinic. THC dominant medical cannabis is the one with a dominant content of Δ-9-tetrahydrocannabinol

ISSN: 2522-5782